It has been demonstrated that the PPARγ agonist rosiglitazone can reduce hepatic inflammation and associated biomarkers in a methionine- and choline-deficient diet mouse model of nonalcoholic steatohepatitis [29]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.